Minimal residual disease (MRD) in acute myelogenous leukemia (AML) is emerging as an independent risk factor for disease relapse and has significant potential to guide therapeutic decisions. However, current methods for detecting gene mutation-based MRD are limited by a lack of broad application to multiple gene targets or by technological barriers preventing adequate sensitivity. In this webinar, Dr. Brian Parkin of the University of Michigan discussed the use of the RainDance Thunderbolts™ Myeloid Panel to identify AML-related gene mutations to serve as targets for MRD detection. He then described the use of RainDance RainDrop technology for quantifying residual leukemia-associated mutations in bone marrow samples of patients in complete morphological remission.
Dr. Brian Parkin is a physician-scientist and Clinical Lecturer of Internal Medicine in the Division of Hematology/Oncology at the University of Michigan, where he completed residency in Internal Medicine and a fellowship in Hematology and Oncology. His research focuses on the characterization and prognostic impact of genomic minimal residual disease in acute myelogenous leukemia (AML) as well as determining the mechanisms of AML therapy resistance and relapse before and after allogeneic stem cell transplantation.